TVTX · Travere Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Dube Eric M Chief Executive Officer | ▼ Sell | Open Market | 432,886 Shares held | 9/17/2026 | View profile |
| ASELAGE STEVE Director | ▼ Sell | Open Market | 146,919 Shares held | 5/11/2022 | View profile |
| Heerma Peter Chief Commercial Officer | ▼ Sell | Open Market | 117,066 Shares held | 9/17/2026 | View profile |
| REED ELIZABETH E SVP, GC & Corporate Secretary | ▼ Sell | Open Market | 105,389 Shares held | 9/15/2026 | View profile |
| Inrig Jula Chief Medical Officer | ▼ Sell | Open Market | 100,491 Shares held | 9/15/2026 | View profile |
| ROTE WILLIAM E. Senior Vice President, R&D | ▼ Sell | Open Market | 98,197 Shares held | 9/16/2026 | View profile |
| Meckler Jeffrey A CEO and Director | ▼ Sell | Open Market | 91,500 Shares held | 9/10/2026 | View profile |
| Cline Christopher R. Chief Financial Officer | ▼ Sell | Open Market | 87,508 Shares held | 9/15/2026 | View profile |
| Gary A. Lyons Director | ▼ Sell | Open Market | 61,500 Shares held | 8/18/2026 | View profile |
| Timothy Coughlin Director | ▼ Sell | Open Market | 56,250 Shares held | 6/12/2026 | View profile |
| Calvin Sandra VP, Corp Controller and CAO | ▼ Sell | Open Market | 42,353 Shares held | 9/15/2026 | View profile |
| Roy D. Baynes Director | ▼ Sell | Open Market | 41,500 Shares held | 6/12/2026 | View profile |
| Ron Squarer Director | ▲ Buy | Grant | 39,375 Shares held | 5/19/2026 | View profile |
| John A. Orwin Director | ▲ Buy | Grant | 39,375 Shares held | 5/19/2026 | View profile |
| Clague Laura Chief Financial Officer | ▼ Sell | Open Market | 35,655 Shares held | 5/11/2022 | View profile |
| Poole Sandra Director | ▲ Buy | Grant | 34,000 Shares held | 5/19/2026 | View profile |
| Suzanne Louise Bruhn Director | ▲ Buy | Grant | 32,750 Shares held | 5/19/2026 | View profile |
| Williams Brinkley Ruth Director | ▲ Buy | Grant | 29,750 Shares held | 5/19/2026 | View profile |
Transaction History
| Heerma Peter | ▲ Buy | Option Exercise | 8,282 | $186K | 9/17/2026 |
| Heerma Peter | ▼ Sell | Open Market | 8,282 | $539K | 9/17/2026 |
| Dube Eric M | ▲ Buy | Option Exercise | 108,493 | $2.5M | 9/17/2026 |
| Dube Eric M | ▼ Sell | Open Market | 101,691 | $6.6M | 9/17/2026 |
| Dube Eric M | ▼ Sell | Open Market | 6,802 | $442K | 9/17/2026 |
| ROTE WILLIAM E. | ▲ Buy | Option Exercise | 350 | $6K | 9/16/2026 |
| ROTE WILLIAM E. | ▲ Buy | Option Exercise | 55,000 | $850K | 9/16/2026 |
| ROTE WILLIAM E. | ▲ Buy | Option Exercise | 57,500 | $1.5M | 9/16/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 65,104 | $4.1M | 9/16/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 47,746 | $3.0M | 9/16/2026 |
| Heerma Peter | ▼ Sell | Open Market | 93,604 | $5.9M | 9/16/2026 |
| Heerma Peter | ▼ Sell | Open Market | 79,113 | $5.0M | 9/16/2026 |
| Heerma Peter | ▲ Buy | Option Exercise | 100,000 | $1.1M | 9/16/2026 |
| Heerma Peter | ▲ Buy | Option Exercise | 55,000 | $850K | 9/16/2026 |
| Heerma Peter | ▲ Buy | Option Exercise | 17,717 | $476K | 9/16/2026 |
| Dube Eric M | ▲ Buy | Option Exercise | 195,841 | $4.6M | 9/16/2026 |
| Dube Eric M | ▼ Sell | Open Market | 99,716 | $6.3M | 9/16/2026 |
| Dube Eric M | ▼ Sell | Open Market | 96,125 | $6.1M | 9/16/2026 |
| Calvin Sandra | ▼ Sell | Open Market | 4,275 | $266K | 9/15/2026 |
| Calvin Sandra | ▼ Sell | Open Market | 800 | $50K | 9/15/2026 |
| Calvin Sandra | ▼ Sell | Open Market | 300 | $19K | 9/15/2026 |
| ROTE WILLIAM E. | ▲ Buy | Option Exercise | 39,000 | $985K | 9/15/2026 |
| ROTE WILLIAM E. | ▲ Buy | Option Exercise | 39,650 | $712K | 9/15/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 63,907 | $4.0M | 9/15/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 29,021 | $1.8M | 9/15/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 3,000 | $191K | 9/15/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 270 | $18K | 9/15/2026 |
| Heerma Peter | ▲ Buy | Option Exercise | 39,283 | $1.1M | 9/15/2026 |
| Heerma Peter | ▲ Buy | Option Exercise | 1,381 | $31K | 9/15/2026 |
| Heerma Peter | ▲ Buy | Option Exercise | 36,526 | $326K | 9/15/2026 |
| Heerma Peter | ▼ Sell | Open Market | 71,938 | $4.5M | 9/15/2026 |
| Heerma Peter | ▼ Sell | Open Market | 27,421 | $1.7M | 9/15/2026 |
| Heerma Peter | ▼ Sell | Open Market | 1,400 | $89K | 9/15/2026 |
| Heerma Peter | ▼ Sell | Open Market | 1,431 | $93K | 9/15/2026 |
| Inrig Jula | ▲ Buy | Option Exercise | 32,395 | $289K | 9/15/2026 |
| Inrig Jula | ▼ Sell | Open Market | 25,390 | $1.6M | 9/15/2026 |
| Inrig Jula | ▼ Sell | Open Market | 17,284 | $1.1M | 9/15/2026 |
| Inrig Jula | ▼ Sell | Open Market | 1,600 | $102K | 9/15/2026 |
| Inrig Jula | ▼ Sell | Open Market | 400 | $26K | 9/15/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 37,500 | $580K | 9/15/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 21,926 | $1.4M | 9/15/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 13,874 | $869K | 9/15/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 1,400 | $89K | 9/15/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 300 | $20K | 9/15/2026 |
| Dube Eric M | ▲ Buy | Option Exercise | 95,666 | $2.2M | 9/15/2026 |
| Dube Eric M | ▼ Sell | Open Market | 63,498 | $3.9M | 9/15/2026 |
| Dube Eric M | ▼ Sell | Open Market | 28,796 | $1.8M | 9/15/2026 |
| Dube Eric M | ▼ Sell | Open Market | 3,102 | $197K | 9/15/2026 |
| Dube Eric M | ▼ Sell | Open Market | 270 | $18K | 9/15/2026 |
| Cline Christopher R. | ▲ Buy | Option Exercise | 20,000 | $349K | 9/15/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 27,473 | $1.7M | 9/15/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 20,735 | $1.3M | 9/15/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 1,900 | $121K | 9/15/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 400 | $26K | 9/15/2026 |
| Calvin Sandra | ▲ Buy | Option Exercise | 2,500 | $69K | 9/15/2026 |
| Calvin Sandra | ▲ Buy | Option Exercise | 1,250 | $28K | 9/15/2026 |
| Calvin Sandra | ▲ Buy | Option Exercise | 1,625 | $33K | 9/15/2026 |
| Meckler Jeffrey A | ▲ Buy | Option Exercise | 10,000 | $174K | 9/10/2026 |
| Meckler Jeffrey A | ▲ Buy | Option Exercise | 10,000 | $265K | 9/10/2026 |
| Meckler Jeffrey A | ▼ Sell | Open Market | 1,700 | $111K | 9/10/2026 |
| Meckler Jeffrey A | ▼ Sell | Open Market | 1,200 | $79K | 9/10/2026 |
| Meckler Jeffrey A | ▼ Sell | Open Market | 14,000 | $944K | 9/10/2026 |
| Meckler Jeffrey A | ▼ Sell | Open Market | 3,100 | $211K | 9/10/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 642 | $43K | 9/2/2026 |
| Gary A. Lyons | ▲ Buy | Option Exercise | 5,000 | $87K | 8/18/2026 |
| Gary A. Lyons | ▼ Sell | Open Market | 4,100 | $259K | 8/18/2026 |
| Gary A. Lyons | ▼ Sell | Open Market | 900 | $57K | 8/18/2026 |
| Gary A. Lyons | ▲ Buy | Option Exercise | 5,000 | $87K | 8/17/2026 |
| Gary A. Lyons | ▼ Sell | Open Market | 500 | $32K | 8/17/2026 |
| Gary A. Lyons | ▼ Sell | Open Market | 1,900 | $119K | 8/17/2026 |
| Gary A. Lyons | ▼ Sell | Open Market | 2,600 | $165K | 8/17/2026 |
| Inrig Jula | ▼ Sell | Gift | 468 | $0 | 6/22/2026 |
| Timothy Coughlin | ▲ Buy | Option Exercise | 10,000 | $265K | 6/12/2026 |
| Timothy Coughlin | ▼ Sell | Open Market | 10,000 | $501K | 6/12/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 4,500 | $96K | 6/12/2026 |
| Roy D. Baynes | ▼ Sell | Open Market | 4,500 | $225K | 6/12/2026 |
| Poole Sandra | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| John A. Orwin | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| Suzanne Louise Bruhn | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| Roy D. Baynes | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| Ron Squarer | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| Williams Brinkley Ruth | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| Meckler Jeffrey A | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| Gary A. Lyons | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| Timothy Coughlin | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 |
| Timothy Coughlin | ▼ Sell | Open Market | 3,250 | $141K | 5/15/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 2,763 | $121K | 5/6/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 2,076 | $91K | 5/6/2026 |
| Inrig Jula | ▼ Sell | Open Market | 311 | $14K | 5/6/2026 |
| Dube Eric M | ▼ Sell | Open Market | 22,500 | $989K | 5/6/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 310 | $14K | 5/6/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 2,174 | $101K | 5/5/2026 |
| Heerma Peter | ▼ Sell | Open Market | 2,174 | $101K | 5/5/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 2,181 | $102K | 5/5/2026 |
| Inrig Jula | ▼ Sell | Open Market | 2,174 | $101K | 5/5/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 4,500 | $82K | 5/5/2026 |
| Roy D. Baynes | ▼ Sell | Open Market | 4,500 | $210K | 5/5/2026 |
| ROTE WILLIAM E. | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 20,000 | $359K | 5/4/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 20,000 | $900K | 5/4/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 |
| Inrig Jula | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 |
| Heerma Peter | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 |
| Dube Eric M | ▲ Buy | Option Exercise | 22,500 | $0 | 5/4/2026 |
| Cline Christopher R. | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 |
| Meckler Jeffrey A | ▲ Buy | Option Exercise | 8,000 | $131K | 5/4/2026 |
| Meckler Jeffrey A | ▼ Sell | Open Market | 8,000 | $360K | 5/4/2026 |
| Inrig Jula | ▲ Buy | Option Exercise | 20,000 | $448K | 5/4/2026 |
| Inrig Jula | ▼ Sell | Open Market | 20,000 | $900K | 5/4/2026 |
| Roy D. Baynes | ▼ Sell | Open Market | 9,750 | $431K | 5/1/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 9,750 | $66K | 5/1/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 9,100 | $356K | 4/22/2026 |
| Dube Eric M | ▼ Sell | Open Market | 56,815 | $2.3M | 4/15/2026 |
| Dube Eric M | ▼ Sell | Open Market | 20 | $853 | 4/15/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 1,559 | $66K | 4/15/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 1,014 | $43K | 4/15/2026 |
| Inrig Jula | ▼ Sell | Open Market | 1,018 | $43K | 4/15/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 5,226 | $218K | 4/15/2026 |
| Dube Eric M | ▼ Sell | Open Market | 7,165 | $299K | 4/15/2026 |
| Gary A. Lyons | ▲ Buy | Option Exercise | 8,000 | $131K | 4/14/2026 |
| Gary A. Lyons | ▼ Sell | Open Market | 8,000 | $329K | 4/14/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 8,000 | $144K | 4/14/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 4,500 | $82K | 4/14/2026 |
| Roy D. Baynes | ▼ Sell | Open Market | 6,750 | $284K | 4/14/2026 |
| Calvin Sandra | ▲ Buy | Option Exercise | 2,500 | $56K | 4/14/2026 |
| Calvin Sandra | ▲ Buy | Option Exercise | 6,250 | $56K | 4/14/2026 |
| Calvin Sandra | ▲ Buy | Option Exercise | 6,500 | $133K | 4/14/2026 |
| Calvin Sandra | ▼ Sell | Open Market | 21,977 | $903K | 4/14/2026 |
| Heerma Peter | ▼ Sell | Open Market | 7,215 | $303K | 4/14/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 9 | $370 | 4/14/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 7,239 | $304K | 4/14/2026 |
| Inrig Jula | ▼ Sell | Open Market | 7,215 | $303K | 4/14/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 4,500 | $96K | 4/14/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 6,750 | $115K | 4/14/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 9,000 | $139K | 4/14/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 10,000 | $191K | 4/14/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 20,000 | $359K | 4/14/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 7,500 | $116K | 4/14/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 37,500 | $1.5M | 4/14/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 7,215 | $303K | 4/14/2026 |
| Roy D. Baynes | ▼ Sell | Open Market | 26,000 | $1.1M | 4/14/2026 |
| ROTE WILLIAM E. | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 |
| Dube Eric M | ▲ Buy | Grant | 64,000 | $0 | 4/13/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 65 | $2K | 4/13/2026 |
| Inrig Jula | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 |
| Cline Christopher R. | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 |
| REED ELIZABETH E | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 |
| Heerma Peter | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 |
| Roy D. Baynes | ▲ Buy | Option Exercise | 10,000 | $265K | 4/6/2026 |
| Roy D. Baynes | ▼ Sell | Open Market | 10,000 | $330K | 4/6/2026 |
| Dube Eric M | ▼ Sell | Open Market | 34,902 | $1.1M | 4/1/2026 |
| Dube Eric M | ▼ Sell | Open Market | 25,098 | $790K | 4/1/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 10,000 | $155K | 4/1/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 10,000 | $300K | 4/1/2026 |
| Dube Eric M | ▲ Buy | Option Exercise | 60,000 | $928K | 4/1/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 10,000 | $191K | 3/16/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 10,000 | $281K | 3/16/2026 |
| Dube Eric M | ▲ Buy | Option Exercise | 60,000 | $928K | 2/20/2026 |
| Dube Eric M | ▼ Sell | Open Market | 60,000 | $1.8M | 2/20/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 5,679 | $156K | 2/17/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 4,321 | $122K | 2/17/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 10,000 | $191K | 2/17/2026 |
| Inrig Jula | ▼ Sell | Open Market | 1,547 | $50K | 2/4/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 2,485 | $80K | 2/4/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 110 | $4K | 2/4/2026 |
| Inrig Jula | ▼ Sell | Open Market | 232 | $8K | 2/4/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 1,635 | $53K | 2/4/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 509 | $17K | 2/4/2026 |
| Dube Eric M | ▼ Sell | Open Market | 66,452 | $2.1M | 2/3/2026 |
| Dube Eric M | ▼ Sell | Open Market | 33,635 | $1.1M | 2/3/2026 |
| Inrig Jula | ▼ Sell | Open Market | 6,956 | $223K | 2/3/2026 |
| Heerma Peter | ▼ Sell | Open Market | 7,310 | $235K | 2/3/2026 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 12,446 | $409K | 2/3/2026 |
| Calvin Sandra | ▼ Sell | Open Market | 4,333 | $139K | 2/3/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 7,175 | $230K | 2/3/2026 |
| Cline Christopher R. | ▼ Sell | Open Market | 7,242 | $233K | 2/3/2026 |
| Cline Christopher R. | ▲ Buy | Grant | 28,130 | $0 | 1/31/2026 |
| Heerma Peter | ▲ Buy | Grant | 26,120 | $0 | 1/31/2026 |
| REED ELIZABETH E | ▲ Buy | Grant | 25,110 | $0 | 1/31/2026 |
| ROTE WILLIAM E. | ▲ Buy | Grant | 20,090 | $0 | 1/31/2026 |
| Inrig Jula | ▲ Buy | Grant | 28,130 | $0 | 1/31/2026 |
| Calvin Sandra | ▲ Buy | Grant | 15,180 | $0 | 1/31/2026 |
| Dube Eric M | ▲ Buy | Grant | 113,800 | $0 | 1/31/2026 |
| Dube Eric M | ▲ Buy | Option Exercise | 51,865 | $802K | 1/27/2026 |
| Dube Eric M | ▼ Sell | Open Market | 51,865 | $1.6M | 1/27/2026 |
| Dube Eric M | ▲ Buy | Option Exercise | 8,135 | $126K | 1/23/2026 |
| Dube Eric M | ▼ Sell | Open Market | 8,135 | $244K | 1/23/2026 |
| REED ELIZABETH E | ▲ Buy | Option Exercise | 10,000 | $191K | 1/20/2026 |
| REED ELIZABETH E | ▼ Sell | Open Market | 10,000 | $273K | 1/20/2026 |
| Inrig Jula | ▼ Sell | Open Market | 445 | $17K | 1/6/2026 |
| Inrig Jula | ▼ Sell | Open Market | 2,031 | $82K | 1/5/2026 |
| Heerma Peter | ▼ Sell | Open Market | 4,980 | $199K | 12/24/2025 |
| ROTE WILLIAM E. | ▲ Buy | Option Exercise | 60,000 | $1.2M | 12/24/2025 |
| Inrig Jula | ▲ Buy | Option Exercise | 15,000 | $134K | 12/24/2025 |
| ROTE WILLIAM E. | ▼ Sell | Open Market | 60,000 | $2.4M | 12/24/2025 |
| Inrig Jula | ▼ Sell | Open Market | 15,000 | $630K | 12/24/2025 |
| Calvin Sandra | ▼ Sell | Open Market | 7,402 | $296K | 12/24/2025 |
| Calvin Sandra | ▼ Sell | Open Market | 2,910 | $105K | 12/15/2025 |
| Cline Christopher R. | ▲ Buy | Option Exercise | 20,000 | $325K | 12/1/2025 |
| Cline Christopher R. | ▼ Sell | Open Market | 20,000 | $700K | 12/1/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.